{"id":48484,"date":"2025-11-17T20:07:14","date_gmt":"2025-11-17T12:07:14","guid":{"rendered":"https:\/\/flcube.com\/?p=48484"},"modified":"2025-11-17T20:07:17","modified_gmt":"2025-11-17T12:07:17","slug":"suzhou-zelgen-biopharma-to-deregister-u-s-subsidiary-gensun-to-sharpen-rd-focus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48484","title":{"rendered":"Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus"},"content":{"rendered":"\n

Suzhou Zelgen Biopharmaceuticals Co.,\u202fLtd.<\/strong> (SHA: 688266<\/a>) announced plans to de\u2011register and cancel<\/strong> its U.S. subsidiary, Gensun Biopharma\u202fInc.<\/strong> The move is aimed at streamlining resource allocation, tightening internal governance, cutting R&D overhead, and boosting drug\u2011development productivity.<\/p>\n\n\n\n

Company & Subsidiary Overview<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Parent<\/strong><\/td>Suzhou\u202fZelgen\u202fBiopharmaceuticals (Shanghai-listed)<\/td><\/tr>
Subsidiary<\/strong><\/td>Gensun\u202fBiopharma\u202fInc. (Founded 3\u202fFeb\u202f2016)<\/td><\/tr>
Equity Ownership<\/strong><\/td>100\u202f% held by Zelgen through\u202fZelgen\u202fHoldings Ltd.<\/td><\/tr>
Primary Role<\/strong><\/td>Early\u2011stage antibody research: molecular design and limited in\u2011vitro screening<\/td><\/tr>
Parent\u2019s Responsibilities<\/strong><\/td>Antibody CMC, pre\u2011clinical pharmacology\/\u200btoxicology, and all clinical studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

For the past decade, the two entities collaborated on large\u2011molecule antibody discovery, but the bulk of CMC, pre\u2011clinical, and clinical work has always been performed by the Shanghai parent. 2025 sees the technology\u2011platform integration<\/strong> completed, reducing the need for a geographically isolated R&D arm.<\/p>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n